Document Detail

Nerve growth factor (NGF): a potential urinary biomarker for overactive bladder syndrome (OAB)?
MedLine Citation:
PMID:  23444927     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: To review the current literature on the use of urinary nerve growth factor (NGF) as a potential biomarker for overactive bladder syndrome (OAB).
METHOD: A comprehensive electronic literature search was conducted using the PubMed database to identify publications relating to urinary NGF.
RESULTS: There are a growing number of publications that have measured urinary NGF levels in different types of bladder dysfunction. These range from OAB, bladder pain syndrome, idiopathic and neurogenic detrusor overactivity, bladder oversensitivity and bladder outflow obstruction. Urinary NGF levels do appear to be raised in these pathological states when compared with healthy control samples. In patients with OAB, these raised urinary NGF levels appear to also reduce after successful treatment with antimuscarinics and botulinum toxin A, which indicates a potential use in monitoring responses to treatment. However, raised levels are not limited to OAB, which questions its specificity. Urinary NGF measurements are performed with an enzyme-linked immunosorbent assay using polyclonal antibodies to NGF. The technique requires standardisation, and the different antibodies to NGF require validating. Also a definition of what is the 'normal' range of NGF in urine is still required before it can be used as a diagnostic and prognostic tool.
CONCLUSIONS: Whilst the evidence for an increased urinary NGF in OAB appears convincing, many questions about its validity remain including: specificity, sensitivity, cost- and time-effectiveness. Many criteria for what constitutes a biomarker still need to be evaluated and met before this molecule can be considered for this role.
Jai H Seth; Arun Sahai; Mohammad S Khan; Frank van der Aa; Dirk de Ridder; Jalesh N Panicker; Prokar Dasgupta; Clare J Fowler
Related Documents :
9086517 - Maternal serum screening for fetal genetic disorders.
9367007 - Atypicality or specific screen: which is better at detecting non-down's chromosomal ano...
23639747 - A case of prune belly syndrome.
9829057 - Prenatal screening for down syndrome.
19470147 - Transient unilateral horner's syndrome after epidural ropivacaine in a dog.
24975767 - Five polyostotic conditions that general orthopedic surgeons should recognize (or shoul...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  BJU international     Volume:  111     ISSN:  1464-410X     ISO Abbreviation:  BJU Int.     Publication Date:  2013 Mar 
Date Detail:
Created Date:  2013-02-28     Completed Date:  2013-04-29     Revised Date:  2014-02-20    
Medline Journal Info:
Nlm Unique ID:  100886721     Medline TA:  BJU Int     Country:  England    
Other Details:
Languages:  eng     Pagination:  372-80     Citation Subset:  IM    
Copyright Information:
© 2013 BJU International.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Biological Markers / urine
Botulinum Toxins, Type A / therapeutic use
Enzyme-Linked Immunosorbent Assay / methods
Evidence-Based Medicine*
Muscarinic Antagonists / therapeutic use
Nerve Growth Factor / urine*
Neuromuscular Agents / therapeutic use
Sensitivity and Specificity
Treatment Outcome
Urinary Bladder, Overactive / drug therapy,  physiopathology,  urine*
Grant Support
MR/J006742/1//Medical Research Council; //Medical Research Council
Reg. No./Substance:
0/Biological Markers; 0/Muscarinic Antagonists; 0/Neuromuscular Agents; 9061-61-4/Nerve Growth Factor; EC Toxins, Type A

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Photodissociation Dynamics of enolic-1,2-cyclohexanedione at 266, 248 and 193 nm: Mechanism and Nasc...
Next Document:  The moderating effect of nutritional status on depressive symptoms in veteran elders with dementia: ...